Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 1:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,613 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: MDD Clear all
Completed Phase 2 Interventional Results available

Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)

NCT01625845
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Symptoms, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Heart Disease
Interventions
Pentoxifylline, Placebo, Standard Treatment
Drug · Other · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 26, 2026, 1:36 AM EDT
Not yet recruiting Not applicable Interventional

Helping Kentuckians Overcome Depression and Opioid Addiction With Brain Stimulation

NCT07842601
View directory record Official record
Conditions
Opioid Use Disorder, Major Depressive Disorder (MDD)
Interventions
Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 26, 2026, 1:36 AM EDT
Completed Phase 3 Interventional

Lethargic Depression Study

NCT00064467
View directory record Official record
Conditions
Epilepsy, Major Depressive Disorder (MDD)
Interventions
Extended-release bupropion (HCl)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
24
States / cities
Beverly Hills, California • Sherman Oaks, California • Temecula, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 26, 2026, 1:36 AM EDT
Completed Not applicable Interventional

Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance

NCT02190968
View directory record Official record
Conditions
Major Depressive Disorder, Recurrent, in Remission, Depressive Symptoms
Interventions
Usual Depression Care, Mindful Mood Balance
Behavioral
Lead sponsor
University of Toronto
Other
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 26, 2026, 1:36 AM EDT
Completed Phase 1 Interventional

Biomarkers of Fast Acting Therapies in Major Depression

NCT02165449
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 26, 2026, 1:36 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder

NCT03093025
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
TS-121 10 mg, TS-121 50 mg, Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 26, 2026, 1:36 AM EDT
Not yet recruiting Not applicable Interventional

Evaluation of an 8-week Behavior Skills-based Virtual Reality Program for Adolescents With Depression. (MDD)

NCT07807735
View directory record Official record
Conditions
Major Depression
Interventions
Virtual reality
Behavioral
Lead sponsor
Edward Via Virginia College of Osteopathic Medicine
Other
Eligibility
13 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 26, 2026, 1:36 AM EDT
Recruiting Phase 2 Interventional

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT06547489
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Zelquistinel
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Birmingham, Alabama • Huntsville, Alabama • Encino, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 26, 2026, 1:36 AM EDT
Withdrawn Not applicable Interventional

Implementing Telemedicine-Based Collaborative Care for MDD in Contract CBOCs

NCT00317018
View directory record Official record
Conditions
Depression
Interventions
Evidence-Based Quality Improvement
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Loma Linda, California • West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Oct 26, 2026, 1:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Transdiagnostic Brain-Behavior Profiling to Enhance Cognitive Behavioral Therapy Response

NCT03175068
View directory record Official record
Conditions
Major Depressive Disorder, Social Anxiety Disorder
Interventions
CBT, ST
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 26, 2026, 1:36 AM EDT
Recruiting Not applicable Interventional

Comparing the Efficacy of Heated Yoga and Sauna as a Treatment for Depression

NCT07082998
View directory record Official record
Conditions
Depression Disorders, Depression - Major Depressive Disorder, Depression Disorder, Depression Chronic, Depression, Depression in Adults
Interventions
heated yoga, sauna, mindfulness app
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 26, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)

NCT01360632
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
OPC-34712 + ADT, Placebo + ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
52
States / cities
Birmingham, Alabama • Costa Mesa, California • Glendale, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 26, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder

NCT01606384
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Oct 26, 2026, 1:36 AM EDT
Terminated Phase 3 Interventional Results available

Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01121536
View directory record Official record
Conditions
Depression
Interventions
Armodafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
66
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 26, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

NCT00566202
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Escitalopram, JNJ-18038683
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 60 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
26
States / cities
Little Rock, Arkansas • Beverly Hills, California • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 26, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

NCT06254612
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SP-624, Placebo
Drug
Lead sponsor
Sirtsei Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 26, 2026, 1:36 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

NCT00411099
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
agomelatine, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
42
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Cerritos, California + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 26, 2026, 1:36 AM EDT
Recruiting Phase 3 Interventional

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06911112
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NBI-1065845, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
17
States / cities
Huntsville, Alabama • Bryant, Arkansas • Glendale, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 26, 2026, 1:36 AM EDT
Recruiting Phase 3 Interventional

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

NCT07775300
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Brenipatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 26, 2026, 1:36 AM EDT
Withdrawn Not applicable Interventional

Late-life Depression and Cerebral Perfusion

NCT01751828
View directory record Official record
Conditions
Depression
Interventions
Sertraline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 26, 2026, 1:36 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder

NCT00467402
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
agomelatine, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
78
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 26, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

Opiate Suicide Study in Patients With Major Depression

NCT04116528
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 26, 2026, 1:36 AM EDT
Completed Phase 1Phase 2 Interventional

Comparison of Two Psychotherapy Treatments for Depressed Women With a History of Sexual Abuse

NCT00257400
View directory record Official record
Conditions
Depression
Interventions
Interpersonal Psychotherapy (IPT), Individual Psychotherapy
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2014 · Synced Oct 26, 2026, 1:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Barefoot Running vs. in Shoes on Physiology and Mood

NCT01733381
View directory record Official record
Conditions
Autonomic Nervous System (ANS) Functioning and Mood State
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 26, 2026, 1:36 AM EDT